Effects of Cortical Dopamine Regulation on Drinking, Craving, and Cognitive Control

Medical University of South Carolina (MUSC)

Status and phase: Completed; Phase 2

Conditions: Alcohol Use Disorder

Treatments: Drug: Placebo; Drug: Tolcapone

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT02949934

Pro00050157

P50AA010761 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The purpose of this study is to determine whether the catechol-O-methyltransferase (COMT) inhibitor tolcapone, relative to placebo, reduces alcohol drinking and alcohol cue-elicited brain activation and increases brain activation associated with cognitive control as a function of a participant's genotype at a polymorphism in the COMT gene.

Enrollment: 90 patients

Sex: All

Ages: 21 to 40 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age 21-40 (to focus on an age group still on a trajectory of increasing alcohol consumption).
2. Meets Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) criteria for current Alcohol Use Disorder.
3. Currently not engaged in, and does not want treatment for, alcohol-related problems.
4. Able to read and understand questionnaires and informed consent.
5. Lives within 50 miles of the study site.
6. Able to maintain abstinence from alcohol for two days (without the aid of detoxification medications), as determined by self report and breathalyzer measurements.

Exclusion criteria

1. Current DSM-5 diagnosis of any other substance use disorder except Nicotine Use Disorder.
2. Any psychoactive substance use (except marijuana and nicotine) within the last 30 days, as indicated by self-report and urine drug screen. For marijuana, no use within the last seven days by verbal report and negative (or decreasing) urine tetrahydrocannibinol (THC) levels.
3. Current DSM-5 Axis I diagnosis, including major depression, panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder, bipolar affective disorder, schizophrenia, dissociative disorders, eating disorders, or any other psychotic or organic mental disorder.
4. Current suicidal ideation or homicidal ideation.
5. Need for maintenance or acute treatment with any psychoactive medication, including antiepileptic medications.
6. Currently taking medication known to affect alcohol intake (e.g., disulfiram, naltrexone, acamprosate, topiramate).
7. History of severe alcohol withdrawal (e.g., seizure, delirium tremens), as evidenced by self-report and assessment with Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar).
8. Clinically significant medical problems such as cardiovascular, renal, gastrointestinal, or endocrine problems that would impair participation or limit medication ingestion.
9. Past alcohol-related medical illness, such as gastrointestinal bleeding, pancreatitis, or peptic ulcer.
10. Current or past hepatocellular disease, as indicated by verbal report or elevations of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than the upper limit of the normal range at screening.
11. Females of childbearing potential who are pregnant (by urine human chorionic gonadotropin), nursing, or who are not using a reliable form of birth control.
12. Current charges pending for a violent crime (not including drinking while intoxicated).
13. Lack of a stable living situation.
14. Presence of ferrous metal in the body, as evidenced by metal screening and self-report.
15. Severe claustrophobia or morbid obesity that preclude placement in the MRI scanner.
16. History of head injury with > 2 minutes of unconsciousness.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

90 participants in 6 patient groups, including a placebo group

Placebo/rs4680 val/val

Placebo Comparator group

Description:

Placebo three times per day for eight days Individuals with the rs4680 val/val genotype

Treatment:

Drug: Placebo

Tolcapone/rs4680 val/val

Active Comparator group

Description:

Tolcapone 100 mg three times per day for three days Tolcapone 200 mg three times per day for five days Individuals with the rs4680 val/val genotype

Treatment:

Drug: Tolcapone

Placebo/rs4680 val/met

Placebo Comparator group

Description:

Placebo three times per day for eight days Individuals with the rs4680 val/met genotype

Treatment:

Drug: Placebo

Tolcapone/rs4680 val/met

Active Comparator group

Description:

Tolcapone 100 mg three times per day for three days Tolcapone 200 mg three times per day for five days Individuals with the rs4680 val/met genotype

Treatment:

Drug: Tolcapone

Placebo/rs4680 met/met

Placebo Comparator group

Description:

Placebo three times per day for eight days Individuals with the rs4680 met/met genotype

Treatment:

Drug: Placebo

Tolcapone/rs4680 met/met

Active Comparator group

Description:

Tolcapone 100 mg three times per day for three days Tolcapone 200 mg three times per day for five days Individuals with the rs4680 met/met genotype

Treatment:

Drug: Tolcapone